News & Insights

A therapy can succeed in clinical trials and still fail in the market. For biotechnology companies and investors, this distinction is critical. Clinical success answers an important question: Does the therapy provide sufficient evidence of safety and efficacy? Commercial success asks a much broader set of questions. Is the improvement meaningful compared with existing treatments? Will physicians prescribe it? Will patients accept it? Will insurers pay for it? Can the compan

Biotechnology is entering a decade in which several technologies will move from scientific promise to industrial scale. The biggest opportunities will emerge where biology, engineering, computation, and manufacturing converge. AI-driven drug discovery will reshape how therapeutic targets, molecules, and development risks are identified. Gene editing and programmable genetic medicines will expand beyond rare diseases toward broader clinical applications. Cell therapies will

Every startup will face uncertainty. Markets shift, customers change priorities, competitors emerge, and technical assumptions are challenged. The first pivot is rarely a sign of failure—it is often the beginning of a stronger strategy. The real question is whether the founder can adapt before circumstances force that change. Adaptability is not measured by how often a founder changes direction. It is measured by how effectively decisions improve when new evidence appears.

Scientific discovery is the starting point of innovation, but not every breakthrough is destined to become a successful product. The challenge is not simply proving that a discovery works, but it is proving that it can create value beyond the laboratory. Commercializable discoveries share several characteristics. They address an unmet market need, solve a problem better than existing alternatives, and can be reproduced reliably at scale. Strong intellectual property, a real

Every year, investors review thousands of scientific discoveries. Many are technically impressive. Only a handful become investable businesses. The difference is not always the quality of the science. More often, it is the ability to create commercial value. Interesting science expands knowledge. Investable science solves an important problem with a practical, scalable solution. Investors are looking for technologies that can survive outside the laboratory and create sustai

Every year, researchers publish discoveries with the potential to transform medicine, engineering, and technology. But only a small percentage ever become products that reach the market. The reason is not usually poor science. More often, the problem is the gap between discovery and execution. A breakthrough in the laboratory proves that something is possible. It does not prove that it can be manufactured, regulated, adopted, or delivered at scale. Product development requi

The next decade will not be defined by software alone. The largest opportunities are increasingly emerging from the convergence of science, engineering, and entrepreneurship. By 2035, investors will be searching for technologies capable of solving fundamental challenges in health, energy, manufacturing, food production, and human performance. Here are ten scientific fields likely to attract significant global investment: 1. AI-Driven Drug Discovery Combining artificial inte

Abstract The translation of scientific discoveries into marketable biotechnology products remains one of the most challenging phases in the innovation pipeline. Despite significant advances in molecular biology, genomics, and computational sciences, a large proportion of academic findings fail to reach practical application. This gap, often described as the “first hurdle,” reflects a fundamental misalignment between the objectives of academic research and the requirements of

For decades, the journey from scientific discovery to commercial success has been described as a straight line: make a discovery, publish the results, file a patent, start a company, raise capital, and scale. In reality, this path rarely unfolds in such a clean sequence. Many promising technologies fail not because the science is wrong, but because the process of translation is misunderstood. The Lab-to-Market Transition Model offers a different view. It treats commercializat

Deep tech is entering a defining decade. What was once considered slow, expensive, and uncertain is now becoming the core of global innovation. The shift is not just about new technologies—it is about a new model of how companies are built, funded, and scaled. At its foundation, deep tech is driven by scientific discovery. Breakthroughs in biotechnology, artificial intelligence, advanced materials, and clean energy are no longer isolated research achievements. They are formin

In the era of data-driven healthcare, the fusion of artificial intelligence (AI) and biology is opening up a new frontier in precision medicine. Scientist-entrepreneurs—the bridge between the worlds of research and innovation—are at the forefront of this transformation. By harnessing the power of AI to analyze complex biological data sets, these pioneers are accelerating drug discovery, improving diagnostic accuracy, and personalizing treatment plans in ways never before poss

Across the globe, women scientists are breaking barriers and reshaping the deep tech entrepreneurial landscape. With backgrounds in fields such as biotechnology, artificial intelligence, quantum computing, and materials science, they are not only driving cutting-edge innovation, but are also founding and leading successful startups that are bringing transformative technologies to the market. Deep tech—with its advanced scientific discoveries and engineering innovations—requir

The journey from academic research to commercial innovation is no longer limited to business-savvy entrepreneurs—scientists themselves are increasingly taking on the role of founders and CEOs. With deep technical expertise and a desire to translate their discoveries into real-world impact, these scientist-entrepreneurs are transforming breakthrough research into biotech startups that are redefining healthcare, diagnostics, and therapeutics. At the heart of this transformation